Update on the pathogenesis and treatment of systemic idiopathic arthritis

Current Opinion in Pediatrics

Volumn 23, Issue 6, 2011, Pages 640-646

  Sikora, Keith A ^a   Grom, Alexei A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

anakinra; autoinflammatory; interleukin 1b; interleukin 6; macrophage activation syndrome; systemic juvenile idiopathic arthritis; tocilizumab

Indexed keywords

ABATACEPT; CANAKINUMAB; CORTICOSTEROID; GLUCOCORTICOID; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNITY; CYTOKINES; HUMANS; TREATMENT OUTCOME;

EID: 80955166078     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834cba24     Document Type: Review

References (47)

1. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998; 12:245-271. (Pubitemid 28492906)
2. Silverman ED, Miller JJ, Bernstein B, Shafai T. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 1983; 103:872-876. (Pubitemid 14208185)
3. Stephan JL, Zeller J, Hubert P, et al. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 1993; 11:451-456. (Pubitemid 23287170)
4. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56:956-971.
5. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133-1138. (Pubitemid 46774861)
6. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford) 2005; 44:1350-1353. (Pubitemid 41631856)
7. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006; 2:28-34. (Pubitemid 43153646)
8. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 2004; 430:257-263. (Pubitemid 38902439)
9. Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003; 15:61-69. (Pubitemid 36021025)
10. Nepom BG, Glass DN. Juvenile rheumatoid arthritis and HLA: report of the Park City III workshop. J Rheumatol Suppl 1992; 33:70-74.
11. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376. (Pubitemid 28467565)
12. Ogilvie EM, Fife MS, Thompson SD, et al. The-174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003; 48:3202-3206. (Pubitemid 37409332)
13. Donn RP, Shelley E, Ollier WE. A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001; 44:1782-1785. (Pubitemid 32758224)
14. De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the-173 polymorphism of the macrophage inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003; 48:1398-1407. (Pubitemid 36554539)
15. Fife MS, Gutierrez A, Ogilvie EM, et al. Novel IL10 gene family associations with systemic idiopathic arthritis. Arthritis Res Ther 2006; 8:R148.
16. Date Y, Seki N, Kamizono S, et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of theTNFalpha gene and HLA genes. Arthritis Rheum 1999; 42:2577-2582. (Pubitemid 30327174)
17. Moller JC, Paul D, Ganser G, et al. IL-10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol 2010; 28:912-918.
18. Stock CJ, Ogilvie EM, Samuel JM. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun 2008; 9:349-357. (Pubitemid 351791491)
19. Lamb R, Thomson W, et al., British Society of Paediatric and Adolescent Rheumatology. Positive association of SLC26A2 gene polymorphisms with susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2007; 56:1286-1291. (Pubitemid 46608653)
20. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201:1479-1486. (Pubitemid 40664091)
21. Fall N, Barnes M, Thornton S, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007; 56:3793-3804. (Pubitemid 350100712)
22. Ogilvie EM, Khan A, Hubank M, et al. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56:1954-1965. (Pubitemid 47110394)
23. Barnes MG, Grom AA, Thompson SD. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 2009; 60:2102-2112.
24. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378:88-91.
25. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its patho genesis. Rheumatology 2010; 49:1645-1653.
26. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. J Exp Med 1984; 160:310-316.
27. Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol 1998; 37:1240-1242.
28. Horneff G, Schmeling T, Biedermann I, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2004; 63:1638-1644. (Pubitemid 39573695)
29. Quartier P, Taupin F, Bourdeaut I, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to onset type. Arthritis Rheum 2003; 48:1093-1101. (Pubitemid 36418252)
30. Woo P, Southwood TR, Prieur AM, et al. Randomised placebo-controlled crossover trial with low dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43:1849-1857.
31. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005; 32:935-942. (Pubitemid 40676507)
32. Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treat ment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 2011; 50:189-195.
33. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67:302-308. (Pubitemid 351281262)
34. Quartier P, Allantaz F, Cimaz R, et al. A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS). Ann Rheum Dis 2011; 70:747-754.
35. Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58:1505-151 5. (Pubitemid 351705940)
36. McDermott MF. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today 2009; 45:423-430.
37. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58:2432-2442.
38. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443-2452.
39. Church LD, McDermott MF. Canakinumab: a human anti-IL-1 b monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Expert Rev Clin Immunol 2010; 6:831-841.
40. De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34:1158-1163.
41. De Benedetti F, Pignatti P, Gerloni V, et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997; 24:1403-1409. (Pubitemid 27353389)
42. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single dose, ascending dose of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7:R1281-R1288.
43. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant antiinterleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52:818-825. (Pubitemid 40365104)
44. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371:998-1006. (Pubitemid 351389534)
45. Yutaka I, Ozawa R, Imagawa T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab. Ann Rheum Dis 2011. [Epub ahead of print]
46. Nigrovic P, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63:545-555.
47. Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63:465-482.